GLP-1s Explained: The Good, the Bad, and What Happens After the Weight Comes Off

What Ozempic, Wegovy, Mounjaro, Zepbound and Other Incretin-Based Medications Actually Do—and Why Weight Loss Should Be About More Than the Scale

Today, we will discuss a sensitive topic. While I have my own opinions, I aim to clarify the scientific facts about these popular medications. This article is not intended as medical advice, and my personal views should not substitute the guidance of your qualified healthcare provider. I want this article to be a kick-off for conversation, and I invite you to visit us at Slim Revolution to learn your options for weight loss without the use of pharmaceutical intervention.

Few developments have changed the conversation around weight loss as quickly as GLP-1 medications.

Names like Ozempic, Wegovy, Mounjaro and Zepbound have moved from doctors' offices into television commercials, social media feeds and everyday conversations.

And there is a reason.

These medications can be remarkably effective.

They can improve blood-glucose control in people with Type 2 diabetes, produce substantial weight loss in appropriate patients and, for certain medications and populations, provide additional cardiovascular, kidney or other health benefits.

But powerful medications deserve something better than hype.

They deserve understanding.

At Slim Revolution, our position begins with one rule that overrides everything else in this article:

Your medical provider comes first.

We are coaches. We are not your prescribing physician.

Our role is to help you improve your nutrition, physical activity, strength, body composition and sustainable habits within the medical guidelines established by your healthcare professionals.

If you currently take semaglutide, tirzepatide, liraglutide, exenatide or another prescription medication, do not discontinue it, alter your dose or change your treatment schedule based on this article—or based on advice from a coach.

Starting, stopping and adjusting prescription medications are decisions to make with the clinician responsible for your care.

With that established, let's understand what these medications actually do.

First: What Does “GLP-1” Actually Mean?

GLP-1 stands for:

Glucagon-Like Peptide-1

GLP-1 is an incretin hormone.

That sounds complicated, but the basic concept isn't.

When you eat, your digestive system doesn't simply wait for nutrients to enter your bloodstream and then react.

Your intestines communicate with the rest of your body.

After food arrives, incretin hormones help tell your pancreas and other organs:

“Food is coming. Get ready.”

Two important incretin hormones are:

GLP-1 — glucagon-like peptide-1

and

GIP — glucose-dependent insulinotropic polypeptide.

Most medications commonly called “GLP-1s” activate the GLP-1 receptor.

Tirzepatide is different.

Tirzepatide—sold under the brand names Mounjaro for Type 2 diabetes and Zepbound for chronic weight management and certain other indications—is a dual GIP and GLP-1 receptor agonist.

In other words, it activates signaling pathways associated with both incretin hormones.

What Does GLP-1 Signaling Actually Do?

There are several effects, but three are particularly important for understanding these medications:

1. It increases glucose-dependent insulin secretion.

2. It reduces inappropriate glucagon secretion.

3. It slows gastric emptying and also influences appetite and food intake through the nervous system.

Let's unpack those.

Insulin Does Not “Destroy” Sugar

Insulin is probably one of the most misunderstood hormones in nutrition.

Many people imagine insulin almost like a chemical that enters the bloodstream and consumes glucose.

That's not what happens.

Think of insulin more like a signal.

After carbohydrates are digested, glucose enters your bloodstream.

Your pancreas detects the increase in blood glucose and releases insulin.

Insulin then communicates with insulin-sensitive tissues—including skeletal muscle and adipose tissue—and helps those cells take glucose out of the bloodstream.

Skeletal muscle is particularly important.

Muscle can take up glucose and either use it for energy or store much of it as:

Glycogen.

Glycogen is essentially a readily accessible storage form of carbohydrate that your muscles can later use for energy.

So insulin doesn't “eat” glucose.

It helps tell your body:

“Glucose is available. Move it where it can be used or stored.”

What Goes Wrong in Type 2 Diabetes?

One of the major features of Type 2 diabetes is insulin resistance.

The body may still produce insulin—sometimes very large amounts of it—but tissues do not respond to that insulin signal as effectively as they should.

Imagine someone knocking on a door.

At first, a normal knock gets someone's attention.

Over time, the person inside becomes less responsive.

So you knock harder.

Then harder.

The pancreas often compensates for insulin resistance by producing more insulin.

Eventually, however, pancreatic beta-cell function may no longer keep pace with the body's needs.

Blood glucose remains elevated.

This is one reason incretin-based medications can be extremely valuable in the treatment of Type 2 diabetes.

They improve glucose-dependent insulin secretion and influence several other pathways involved in blood-glucose regulation.

And untreated or inadequately controlled Type 2 diabetes can cause devastating complications.

For an appropriate patient, medication is not “failure.”

It may be an important—and sometimes lifesaving—part of treatment.

Meet Glucagon: Insulin's Counterpart

If insulin helps manage glucose when energy is available, glucagon helps make energy available when blood glucose is falling.

Your liver stores carbohydrate primarily as glycogen.

Between meals, during fasting and during other periods when circulating glucose declines, glucagon signals the liver to release glucose.

You can think of the liver as one of your body's emergency fuel warehouses.

Insulin often communicates:

“We have incoming energy.”

Glucagon helps communicate:

“We need to release some stored energy.”

GLP-1 receptor activation suppresses inappropriately elevated glucagon secretion in a glucose-dependent manner.

That is part of how these medications help reduce excessive blood glucose.

Then There's the Stomach

This is the part most people notice.

GLP-1 receptor agonists can delay gastric emptying.

Normally, food enters the stomach, where it is mechanically and chemically processed, and then gradually moves into the small intestine.

Most nutrient absorption occurs in the small intestine, not the stomach.

So if gastric emptying is slowed, nutrients can reach the intestine—and therefore become available for absorption—more slowly.

That can contribute to feeling full longer.

It can also contribute to some of these medications' most common side effects:

Nausea.

Abdominal discomfort.

Constipation.

Vomiting.

Diarrhea.

Additionally, some individuals experience an uncomfortable feeling of being overly full. These effects aren't imaginary. Gastrointestinal adverse effects are well documented in clinical trials and FDA prescribing information.

Gastric motility and emptying are slowed, which can produce fullness, nausea, bloating and other gastrointestinal symptoms; and in some severe cases, persistent gastrointestinal symptoms require medical evaluation.

Four Medications Worth Knowing

Although there are additional drugs and formulations, four important active ingredients help illustrate the category.

Semaglutide

Common brands include Ozempic for Type 2 diabetes and Wegovy for chronic weight management and other approved indications.

The injectable formulations are typically administered subcutaneously once weekly. Semaglutide also exists in oral formulations for certain indications.

Exenatide

One familiar brand is Byetta.

Byetta is administered by subcutaneous injection twice daily, before the morning and evening meals. Other exenatide formulations have historically used different dosing schedules.

Liraglutide

Common brands include Victoza for Type 2 diabetes and Saxenda for chronic weight management.

Unlike weekly semaglutide, liraglutide is generally administered by subcutaneous injection once daily.

Tirzepatide

Tirzepatide is sold as Mounjaro for Type 2 diabetes and Zepbound for chronic weight management and other approved indications.

It is administered subcutaneously once weekly.

And remember: tirzepatide is not simply a GLP-1 receptor agonist. It activates both GIP and GLP-1 receptors.

Exact doses, escalation schedules and indications differ. Those decisions belong to the prescribing clinician.

Now Let's Talk About the Part the Commercials Don't Make Glamorous

These medications can be effective.

They also have real adverse effects and contraindications.

The most common problems are gastrointestinal:

Nausea.

Vomiting.

Diarrhea.

Abdominal pain.

Constipation.

Delayed gastric emptying can make some patients feel as though a meal remains with them for an unusually long time.

Almost all patients experience some or even all of these symptoms.

And severe or persistent gastrointestinal symptoms should not simply be dismissed as “the medication working.”

FDA labeling also includes warnings or precautions—depending on the particular medication—for potentially serious problems including pancreatitis, gallbladder disease, dehydration-related acute kidney injury and severe gastrointestinal reactions.

Several products also carry a boxed warning concerning thyroid C-cell tumors observed in rodents.

These are prescription medications for a reason.

What About Low Blood Sugar?

This subject deserves particular accuracy.

GLP-1 receptor agonists can lower blood glucose, but their stimulation of insulin secretion is largely glucose-dependent.

That means these medications used alone generally have a much lower risk of severe hypoglycemia than medications that drive insulin independently of glucose levels.

The risk becomes more important when GLP-1 therapy is combined with medications such as insulin or sulfonylureas.

That doesn't mean low blood glucose should ever be ignored.

A glucose measurement below 70 mg/dL is clinically important.

Symptoms can include:

Shakiness.

Sweating.

Hunger.

Weakness or fatigue.

Dizziness.

Confusion.

A conscious person who can safely swallow is generally advised to treat glucose below 70 mg/dL promptly with glucose or another appropriate fast-acting carbohydrate and recheck afterward according to their diabetes-management plan.

More severe hypoglycemia—particularly altered mental status, inability to safely swallow, unconsciousness, seizure, or a situation requiring another person's assistance—is an emergency.

Anyone using glucose-lowering medication should know their own clinician's hypoglycemia plan.

A Personal Observation—and an Important Distinction

There is something I want to share carefully.

I personally know three individuals who required emergency-room care for what they described as dangerous hypoglycemia while being treated with semaglutide.

That concerns me.

But it is equally important to understand what that statement does not mean.

Three people I happen to know are not a clinical study.

It doesn't establish incidence.

It doesn't prove semaglutide alone caused each event.

We don't know from personal observation what other medications, medical conditions, food intake or circumstances contributed.

So I would never present those three cases as scientific evidence.

I present them for exactly what they are:

A personal reminder that prescription medications deserve respect, appropriate screening, patient education and medical supervision.

Anecdotes should make us ask questions.

Good research should help us answer them.

A Note About Kidney Function

Current prescribing information for liraglutide warns about acute kidney injury due to volume depletion, particularly when nausea, vomiting or diarrhea lead to dehydration. Other drugs in this category have their own renal considerations. For example, exenatide is not recommended in severe renal impairment or end-stage renal disease. This is another reason medication selection belongs with a clinician who knows the patient's complete medical history.

Now Let's Talk About the Weight You're Losing

This is where Slim Revolution becomes particularly interested.

We don't care only about making someone lighter.

We care about improving body composition and health.

And those aren't necessarily the same thing.

Every meaningful non-surgical reduction in stored body tissue ultimately requires an energy deficit.

That remains true whether the deficit comes from eating differently, increasing activity, medication-assisted appetite reduction—or some combination of them.

GLP-1 and GIP/GLP-1 medications can make a calorie deficit substantially easier for many people because they can reduce hunger, increase satiety and decrease food intake.

But when body weight decreases, not everything lost is fat.

Yes, Muscle Can Be Lost Too

If you're losing a large amount of weight, preserving lean tissue should be part of the plan.

Don't Just Lose Weight. Give Your Body a Reason to Keep Muscle.

Muscle is metabolically active tissue.

It contributes to strength, mobility, glucose disposal, physical independence and your total daily energy requirements.

And the body needs a reason to maintain it.

One of the strongest signals is:

Resistance training.

Adequate dietary protein also matters. That is why many people are shocked when our nutrition guidance is for a substantial increase in complete protein intake.

That is why someone undergoing medically supervised pharmacological weight management shouldn't necessarily think: “The injection is working, so I don't need to exercise.”

That is exactly when a thoughtful body-composition strategy becomes valuable.

The goal shouldn't simply be:

Lose as much weight as possible.

It should be:

Lose excess fat while preserving as much functional lean tissue as reasonably possible.

What Happens If You Stop?

This is another subject where the data deserve more attention than the marketing.

Adults with overweight or obesity who had received semaglutide 2.4 mg plus lifestyle intervention lost an average of 17.3% of their starting body weight during 68 weeks of treatment. After treatment was discontinued, participants regained approximately two-thirds of their prior weight loss over the following year.

That's substantial!

Weight regain after discontinuation is common.

The medication was helping alter appetite, satiety and food intake.

Remove that assistance and the biological pressures involved in obesity haven't necessarily disappeared.

This Is Where Muscle Matters Again

Imagine someone begins at a certain body weight and basal metabolic rate.

They lose a substantial amount of weight.

Some of that loss is fat.

Some is lean tissue.

A smaller body generally requires less energy than a larger body, and loss of metabolically active tissue can contribute to lower energy expenditure.

Now imagine appetite returns toward its previous level after medication is discontinued.

What once felt like a normal amount of food may now represent considerably more energy relative to the person's smaller body and lower total energy requirements.

That creates an environment in which regain can occur.

Which brings us back to the habits that medication cannot permanently outsource:

Nutrition skills.

Strength.

Movement.

Sleep.

Understanding energy balance.

Learning how to maintain your new body.

Those skills matter whether someone uses medication or not.

Is Long-Term Treatment a Pharmaceutical Conspiracy?

You'll sometimes hear the claim that pharmaceutical companies intentionally want patients trapped on these medications forever.

Obesity itself is increasingly treated medically as a chronic, relapsing disease.

Clinical trials showing substantial regain after discontinuation are one reason physicians may recommend ongoing treatment for appropriate patients.

It creates an important question every patient deserves to discuss with their clinician before starting treatment:

“What is our long-term plan?”

If the answer is indefinite treatment, understand why.

If the goal is eventual discontinuation, ask how nutrition, physical activity, resistance training and behavioral strategies will be developed along the way.

Medication should come with a strategy—not simply a prescription.

Where Slim Revolution Stands

Slim Revolution takes a deliberately conservative approach to pharmacological weight management.

For otherwise healthy individuals seeking primarily cosmetic or moderate weight reduction, our coaching philosophy is to prioritize sustainable nutrition, physical activity, resistance training, sleep, behavior change and other non-pharmacological strategies before medication unless the individual's licensed medical provider recommends otherwise.

That is our coaching philosophy.

For people with Type 2 diabetes, obesity or other qualifying conditions, incretin-based medications can be powerful medical tools. In some patients, the health risks of leaving disease inadequately treated are far greater than the risks of appropriately prescribed medication.

We respect that.

What we strongly discourage is casual prescribing.

If someone is offering you these medications without discussing your medical history, contraindications, side effects, nutrition, lean-mass preservation, what to do if you become ill, and what the long-term plan looks like, we believe you deserve a more complete conversation.

If You're Already Taking a GLP-1, We're Still on Your Team

This point is extremely important.

Slim Revolution isn't interested in shaming someone because she uses medication.

And we certainly aren't going to tell someone to disregard her physician.

Quite the opposite.

If your medical provider determines that GLP-1 or GIP/GLP-1 therapy is appropriate, our role as coaches can be to help support the other side of the equation:

Appropriate nutrition.

Adequate protein.

Resistance exercise.

Sustainable physical activity.

Body-composition monitoring.

Building habits that don't disappear when the prescription changes.

That may be where coaching becomes even more valuable.

The Slim Revolution Approach

We believe your body is capable of extraordinary adaptation when you give it the right environment.

Our coaches focus on nutrition, energy balance, body composition and sustainable physical activity.

We combine coaching with technologies such as VacuTherm to help make physical activity more approachable and engaging for people who may not enjoy conventional exercise.

And when resistance training is appropriate, we want it in the conversation because preserving strength and lean tissue matters.

Our philosophy isn't:

Lose weight at any cost.

It is:

Improve the body you're going to live in.

We want you stronger.

We want you healthier.

We want you more energetic.

We want you educated enough to understand why you're getting results.

And we want those results built around habits you can actually live with.

No shame.

No judgment.

And no pretending that one tool is appropriate for every person.

Health. Wellness. Freedom.

Yes, our name says Slim Revolution.

Weight management is part of what we do.

But becoming lighter isn't the ultimate objective.

Health is.

Wellness is.

Capability is.

Freedom is.

Our job is to help you build the strongest nutrition, movement and lifestyle foundation possible.

Because a revolution shouldn't make you dependent on another fad.

A revolution should give you greater control over your health.

And ultimately...

Revolution leads to freedom.

Recommended Reading

U.S. Food and Drug Administration — Wegovy (semaglutide) Prescribing Information Current FDA prescribing information covering indications, dosing, mechanism, adverse reactions, contraindications and warnings. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf?utm_source=chatgpt.com

U.S. Food and Drug Administration — Ozempic (semaglutide) Prescribing Information FDA prescribing information for semaglutide in Type 2 diabetes and associated approved indications. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035%2C209637s037lbl.pdf?utm_source=chatgpt.com

U.S. Food and Drug Administration — Mounjaro (tirzepatide) Prescribing Information FDA information on the dual GIP/GLP-1 receptor agonist tirzepatide. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf?utm_source=chatgpt.com

Look M, Dunn JP, Kushner RF, et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. The DXA substudy found that approximately 75% of weight lost was fat mass and approximately 25% was lean mass. https://pubmed.ncbi.nlm.nih.gov/39996356/?utm_source=chatgpt.com

Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. Participants regained approximately two-thirds of their previous weight loss during the year after semaglutide and lifestyle intervention were discontinued. https://pubmed.ncbi.nlm.nih.gov/35441470/?utm_source=chatgpt.com

American Diabetes Association — Standards of Care in Diabetes: Glycemic Goals and Hypoglycemia Useful guidance for understanding the definition, recognition and treatment of hypoglycemia. https://diabetesjournals.org/care/article-pdf/48/Supplement_1/S128/791506/dc25s006.pdf?utm_source=chatgpt.com